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Abstract
Immunotherapy in patients with Alzheimer's disease (AD) is rapidly becoming a hot topic of
modern geriatric and clinical gerontology. Current views see immunization with Aβ peptide, the
amyloidogenic protein found in senile plaque of AD patient's brains, or the infusion of preformed
antibody specific for human Aβ, as possible therapeutic approaches to improve the cognitive status
in the disease. Animal models of the disease have provided positive results from both approaches.
Thus, an initial clinical trial using immunization with human Aβ in AD patients was started, but then
shortly halted because of an unusually high incidence (6%) of meningoencephalitis. A long and
currently ongoing debate in the scientific community about the pro or contra of vaccination or
passive immunization with Aβ in AD is thereafter started. Here, the authors would like to stress
few points of concern regarding these approaches in clinical practice.
Immunotherapy in patients with Alzheimer's disease
(AD) is rapidly becoming a hot topic of modern geriatric
and clinical gerontology. M.E. Weksler [1] in the article
entitled "The immunotherapy of Alzheimer's disease"
published in Immunity and Ageing discussed this theme.
Current views see immunization with Aβ peptide, the
amyloidogenic protein found in senile plaque of AD
patient's brains, or the infusion of preformed antibody
specific for human Aβ, as possible therapeutic approaches
to improve the cognitive status in the disease.
Animal models of the disease have provided positive
results from both approaches, since either vaccination
with human Aβ or infusion of preformed antibodies spe-
cific for Aβ, have resulted in a decrease of amyloid plaques
density in the brain of amyloid precursor protein (APP)
transgenic mice [2,3]. Improved memory performances
after Aβ vaccine on APP transgenic mice have also been
claimed [4]. Several other studies from transgenic mice
have there after reinforced the suggestion that vaccination
or passive immunotherapy might result in a relevant clin-
ical effect in human patients (see the Weksler article [1]).
An initial clinical trial using immunization with human
Aβ in AD patients was started and then shortly halted
because of an unusually high incidence (6%) of menin-
goencephalitis (see the Weksler article [1]). A long and
currently ongoing debate in the scientific community
about the pro or contra of vaccination or passive immuni-
zation with Aβ in AD is thereafter started.
Here, we would like to stress few points of concern regard-
ing these approaches in clinical practice.
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1) The claimed animal model for AD is unfortunately
incomplete even if useful model for the human disease.
2) Vaccination with human Aβ in mice induces an
immune response against a foreign protein, i.e. human
Aβ, and the mouse Aβ homolog does not appear to be
involved. On the contrary, Aβ vaccination in man may
potentially induce an autoimmune like disease in the
brain and other peripheral tissues of susceptible patients.
At the moment we do not have the ability to predict which
patients will suffer destructive immune responses.
3) The effects of both vaccination or passive immune ther-
apy in AD brains might be non-specific, as already sug-
gested by a recent report [5] and by the original
histopathological investigation from AD patients
deceased after meningoencephalitis [6]. This notion was
then reinforced by the report of these authors [7].
4) Vaccine therapy is not always effective in the elderly,
since immune defects of variable degree are often present
in old persons [8]. In old clinically ill AD patients this
immune activation might fail or activate noxious auto-
aggressive immune responses. Once again we cannot pre-
dict which patient will experience one or the other condi-
tion after the vaccination.
5) Historically vaccination has been successful in the pre-
vention of the diseases much and much less in the therapy
of ongoing diseases. A significant gain would be achieved
by Aβ vaccination or passive immune therapy, if these
manipulations will work in the very early stages of the dis-
ease. At the moment, no clinical data on this topic are
available and those from animal models have not exten-
sively addressed this topic.
6) A general consideration on AD is also mandatory. In
fact, clinical signs of dementia show up after extensive
synapse and neuron loss have already occurred in the
brain. How can an immune response restore an already
compromised nervous circuit or revive dead neurons? The
very modest decrement of cognitive deterioration rate
claimed in a proportion of AD patients receiving the vac-
cine is a marginal therapeutic goal. In fact, the disease has
not been cured, and the modest clinical slow down in the
AD progression takes big prices, i.e. patients and care giv-
ers will continue to suffer the catastrophic effects of the
disease for a longer time.
We feel that Aβ vaccination and in a less extent passive
immune therapy are now exciting experimental protocols
for animal research and experimental neurology investi-
gations, probably premature for clinical applications.
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